CardioExchange Archive

May 7th, 2015

Selections from Richard Lehman’s Literature Review: May 7th

Richard Lehman, BM, BCh, MRCGP

This week’s topics are a comparison of a retrievable inferior vena cava filter plus anticoagulation vs. anticogulation alone for recurrent PE, the cost effectiveness and population impact of statins for primary prevention in U.S. adults age 75 and older, and more.

---

January 12th, 2015

Selections from Richard Lehman’s Literature Review: January 12th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include the effects of BP reduction in mild hypertension, the association between dietary whole grain intake and risk of mortality, and more.

---

December 8th, 2014

New Anticoagulant Spotlights Major Role for the Intrinsic Pathway

Sanjay Kaul, MD and Ethan J Weiss, M.D.

Sanjay Kaul and Ethan Weiss discuss an entirely new approach to anticoagulation.

---

July 28th, 2014

Selections from Richard Lehman’s Literature Review: July 28th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include a comparison of catheter-directed thrombolysis plus anticoagulation and anticoagulation alone to treat DVT, several papers on dabigatran and bleeding risk, and more.

---

June 17th, 2014

A Meta-Look at Thrombolysis vs. Conventional Anticoagulation for PE

Jay Giri, MD, MPH and Saurav Chatterjee, MD

Jay Giri and Saurav Chatterjee discuss their meta-analysis of trials comparing thrombolytic therapy and conventional anticoagulation in patients at intermediate risk for pulmonary embolism.

---

May 13th, 2014

FDA Study Provides Some Reassurance About Boehringer Ingelheim’s Pradaxa

Larry Husten, PHD

In the latest development in its ongoing review of the new oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim), the FDA today offered largely reassuring news about the sometimes controversial drug. The FDA study of over 134,000 Medicare patients found that dabigatran was associated with a reduced risk for ischemic stroke, bleeding in the brain, and death, compared with […]

---

February 14th, 2014

FDA Once Again Rejects New Indication For Rivaroxaban

Larry Husten, PHD

The third time wasn’t the charm. The FDA today turned turned down — for the third time — the supplemental New Drug Application (sNDA) for rivaroxaban (Xarelto, Johnson & Johnson) for use in acute coronary syndrome patients to reduce MI, stroke, or death. In addition, the FDA — for the second time — turned down the sNDA for rivaroxaban in […]

---

November 4th, 2013

Should Plasma Levels of Dabigatran Guide How We Dose the Drug?

Stuart J Connolly, MD

Stuart J. Connolly discusses his research group’s analysis of data from the RE-LY trial, concerning the relationship between plasma concentrations of dabigatran and the risks for ischemic events and major bleeding.

---

September 18th, 2013

Is Edoxaban the Most Promising of the Novel Anticoagulants?

Samuel Goldhaber, MD

Samuel Z. Goldhaber offers his perspective on the Hokusai-VTE randomized trial comparing edoxaban and warfarin in patients with symptomatic venous thromboembolism.

---

September 12th, 2013

Aspirin Therapy with Anticoagulation in Patients with Afib?

Benjamin A. Steinberg, MD and John Ryan, MD

An interview with Benjamin Steinberg about an analysis of data from the ORBIT-AF registry, in which patients with atrial fibrillation who were taking oral anticoagulation and aspirin had a higher risk of bleeding than patients on anticoagulation only.

---